SAN MATEO, CA. – March 23, 2026 – Kali Therapeutics, a biotechnology company focused on the discovery and development of next-generation biologics, today announced that they have entered into a license agreement with Sanofi for a tri-specific T-cell engager, which has the potential to treat a broad range of B cell-mediated autoimmune diseases. Under the agreement, Sanofi will obtain exclusive worldwide rights to KT501, a novel tri-specific antibody utilizing Kali Therapeutics

SAN MATEO, Calif. – March 18, 2026 –  Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, today announced that dosing is underway for the first cohort of patients in its Phase 1a clinical trial evaluating KT501. KT501 is a first-in-class CD19xBCMAxCD3 trispecific T-cell engager (TCE). The study is being conducted in adult patients with Rheumatoid Arthritis (RA). A Transformative Milestone for Kali Therapeutics The d

Kali Therapeutics Announces Upcoming Poster Presentations at the American College of Rheumatology (ACR) Convergence 2025